BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld MedTech
Home
» Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants
Sep. 1, 2017
By
Omar Ford
No Comments
Abbott Laboratories has initiated a U.S. pivotal clinical study evaluating a modified version of its Amplatzer device designed to correct a common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year.
BioWorld MedTech